Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

4D Molecular Therapeutics (FDMT) Income from Continuing Operations (2020 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Income from Continuing Operations for 6 consecutive years, with 19419000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations rose 139.11% to 19419000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 140072000.0 through Dec 2025, up 12.89% year-over-year, with the annual reading at 140072000.0 for FY2025, 12.89% up from the prior year.
  • Income from Continuing Operations for Q4 2025 was 19419000.0 at 4D Molecular Therapeutics, up from 56855000.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 19419000.0 in Q4 2025, with the low at 56855000.0 in Q3 2025.
  • Average Income from Continuing Operations over 5 years is 29008800.0, with a median of 28374500.0 recorded in 2022.
  • The sharpest move saw Income from Continuing Operations plummeted 334.17% in 2024, then skyrocketed 139.11% in 2025.
  • Over 5 years, Income from Continuing Operations stood at 25076000.0 in 2021, then fell by 9.2% to 27382000.0 in 2022, then decreased by 17.86% to 32272000.0 in 2023, then tumbled by 53.85% to 49650000.0 in 2024, then surged by 139.11% to 19419000.0 in 2025.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 19419000.0, 56855000.0, and 54597000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.